| The North American experience with photopheresis. | |
| | |
MedLine Citation:
|
PMID: 10079806 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Photopheresis or extracorporeal photochemotherapy (ECP) is a novel immunomodulatory therapy based upon pheresis of light-sensitive cells. Whole blood is removed from patients who have previously ingested the photosensitizing agent 8-methoxypsoralen (8-MOP) followed by leukapheresis and exposure of the 8-MOP containing white blood cells (WBCs) extracorporeally to an ultraviolet A (UVA) light source prior to their return to the patient. In 1988, the Food and Drug Administration (FDA) approved photopheresis for the treatment of cutaneous T-cell lymphoma (CTCL). Treatment of CTCL with photopheresis has been reported in over 300 patients worldwide. Photopheresis has also demonstrated encouraging results in the treatment of solid organ transplant rejection, graft versus host disease, scleroderma, and other autoimmune diseases although fewer patients have been studied. This review will focus on the North American experience with photopheresis. |
| | |
Authors:
|
J A Zic; J L Miller; G P Stricklin; L E King |
Related Documents
:
|
49796 - Electrolyte disturbances in beer drinkers. a specific "hypo-osmolality syndrome". 8849356 - Skewed distribution of igg fc receptor iia (cd32) polymorphism is associated with renal... 8451396 - Cleansing enema prior to double-contrast barium enema examination: is it necessary? 10895376 - Palindromic rheumatism: effect of dietary manipulation. 10746576 - Occurrence of pathogenic yersinia enterocolitica in norwegian pork products determined ... 14558786 - Metabolism of stevioside and rebaudioside a from stevia rebaudiana extracts by human mi... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Volume: 3 ISSN: 1091-6660 ISO Abbreviation: Ther Apher Publication Date: 1999 Feb |
Date Detail:
|
Created Date: 1999-04-13 Completed Date: 1999-04-13 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 9706703 Medline TA: Ther Apher Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 50-62 Citation Subset: IM |
Affiliation:
|
Division of Dermatology, Vanderbilt University School of Medicine/Nashville Veterans Affairs Medical Center, Tennessee, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Arthritis, Rheumatoid
/
therapy Graft vs Host Disease / therapy Humans Lymphoma, T-Cell, Cutaneous / therapy Methoxsalen / diagnostic use North America Photopheresis* / methods Photosensitizing Agents / diagnostic use Scleroderma, Systemic / therapy |
| Chemical | |
Reg. No./Substance:
|
0/Photosensitizing Agents; 298-81-7/Methoxsalen |
| Comments/Corrections | |
Comment In:
|
Ther Apher. 1999 Nov;3(4):347-8
[PMID:
10608733
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of therapeutic apheresis in the treatment of cancer: a review.
Next Document: Preliminary evaluation study of a prototype hollow fiber membrane for the continuous membrane autotr...